These findings highlight the potential clinical benefits of using molecular subtype-based treatment optimisation in patients with triple-negative breast cancer, suggesting a path for further clinical investigation. Phase 3 randomised clinical trials assessing the efficacy of subtyping-based regimens are now underway.

4 months ago

P2 data • Journal • PD(L)-1 Biomarker

HER-2 (Human epidermal growth factor receptor 2) • AR (Androgen receptor)

Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • Irene (pyrotinib) • albumin-bound paclitaxel • famitinib (SHR 1020) • Airuituo (bevacizumab biosimilar)

6ms

Famitinib, a multi-targeted receptor tyrosine kinase inhibitor, combined with dalpicilib and fulvestrant in advanced HR-positive and HER2-negative breast cancer (SABCS 2023)

However, the role of angiogenesis inhibitors, such as bevacizumab, in these patients (pts) is controversial...Our phase Ib/II trial (NCT05176080, ChiCTR2100053950) aims to evaluate the safety and efficacy of a novel anti-angiogenesis TKI famitinib (F) added to dalpiciclib (D) and ET in advanced HR-positive and HER2-negative BC... The anti-angiogenesis multi-targeted receptor TKI famitinib combined with CDK4/6i and fulvestrant has shown antitumor effects in advanced HR-positive and HER2-negative BC, and no new safety signals were observed.

6 months ago

Metastases

HER-2 (Human epidermal growth factor receptor 2)

HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive

Avastin (bevacizumab) • fulvestrant • AiRuiKang (dalpiciclib) • famitinib (SHR 1020) • Airuituo (bevacizumab biosimilar)

10ms

A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors (ESMO 2023)

No grade 4/5 TRAEs were reported. Table: 1026MO Efficacy outcomes Variables GC/GEJC (1L) GC/GEJC (≥2L) nsqNSCLC All (n=19) CPS≥5 (n=15) All (n=27) CPS≥5 (n=9) All (n=10) Best overall response, n (%) CR 0 0 1 (3.7) 1 (11.1) 0 PR 4 (21.1) 4 (26.7) 8 (29.6) 6 (66.7) 1 (10.0) SD 7 (36.8) 5 (33.3) 5 (18.5) 1 (11.1) 5 (50.0) PD 7 (36.8) 5 (33.3) 12 (44.4) 1 (11.1) 3 (30.0) NE 1 (5.3) 1 (6.7) 1 (3.7) 0 1 (10.0) ORR, % (95% CI) 21.1 (6.1, 45.6) 26.7 (7.8, 55.1) 33.3 (16.5, 54.0) 77.8 (40.0, 97.2) 10.0 (0.3, 44.5) DCR, % (95% CI) 57.9 (33.5-79.7) 60.0 (32.3, 83.7) 51.8 (32.0, 71.3) 88.9 (51.8, 99.7) 60.0 (26.2, 87.8) mPFS, months (95% CI) 4.1 (1.3-NR) 4.1 (1.4-NR) 4.0 (1.4-NR) 10.3 (1.3-NR) 6.2 (1.3-9.9) Conclusions SHR-1701 plus BEV showed encouraging antitumor activity with a favorable safety profile in pts with advanced GC/GEJC and nsqNSCLC.

10 months ago

Clinical • P1/2 data • Combination therapy • Metastases

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)

HER-2 negative

Avastin (bevacizumab) • retlirafusp alfa (SHR-1701) • Airuituo (bevacizumab biosimilar)

over2years

To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC (clinicaltrials.gov)

P3, N=520, Completed, Jiangsu HengRui Medicine Co., Ltd.

over 2 years ago

Clinical • New P3 trial • Combination therapy

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

EGFR mutation • ALK fusion

Avastin (bevacizumab) • carboplatin • paclitaxel • Airuituo (bevacizumab biosimilar)

3years

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC (clinicaltrials.gov)

P2, N=5, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=50 --> 5 | Not yet recruiting --> Terminated; changes in the R&D strategy

3 years ago

Clinical • Enrollment change • Trial termination • Combination therapy

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

AiRuiKa (camrelizumab) • Airuituo (bevacizumab biosimilar)

3years

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)

No abstract available

3 years ago

Clinical • New P2 trial

ALB (Albumin)

Avastin (bevacizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Onivyde (nanoliposomal irinotecan) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

over3years

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (clinicaltrials.gov)

P2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

over 3 years ago

Clinical • New P2 trial

ALB (Albumin)

Avastin (bevacizumab) • Tecentriq (atezolizumab) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)

almost4years

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)

P2; N=96; Recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Jun 2020 --> Jun 2021; Trial primary completion date: Jun 2020 --> Jun 2021

almost 4 years ago

Trial completion date • Trial primary completion date • Clinical

MSLN (Mesothelin)

MSLN positive

Oncomine™ Dx Target Test

Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)